gel-e Receives a Grant to Develop New Internal Use Hemostats:
COLLEGE PARK, Md., Feb. 19, 2018 /PRNewswire/ -- gel-e Inc., announces two new grants that support the development of internal use hemostats.
gel-e has been awarded a $1.4M grant from the Department of Defense (DoD) through the US Army Medical Research and Material Command (USAMRMC) to develop advanced solutions for prolonged field care. The grant supports the development of an expanding foam hemostat for the treatment of internal non-compressible hemorrhage. Internal non-compressible hemorrhage typically results from being struck by shrapnel or a significant concussive force. As an expansion of gel-e's hemostatic platform (see existing FDA clearances at http://www.gel-e.co/news.html), the Company has been optimizing flowable formulations for internal and surgical use. Consequently, certain product candidates have been identified that can be administered in far-forward locations to quickly stabilize internal injuries, allowing time for evacuation of the wounded to a field surgical OR.
Learn more about gel-e's product pipeline at http://www.gel-e.co/products.html.
"We are honored to be working with our military to develop such an important hemostatic application. This project is a natural extension of our previously published work using flowable formulations, from our biopolymer-based platform, to treat aggressive internal bleeding," said Dr. Matthew Dowling, CSO of gel-e. "It is gratifying to have the DoD recognize our technology platform and support the synergy of this project with the expansion of our product line from the broad treatment of external wounds to those arising from combat."
"Internal non-compressible hemorrhage remains the single largest cause of in-combat hemorrhage-related death," said Dr. David King, MD, LTC and former Chief, Division of Trauma Surgery, 86th Combat Support Hospital, Baghdad, Iraq. "The evaluation of new approaches, like the one gel-e is using, will be important to improve outcomes for our wounded service men and women, both on and off the battlefield."
gel-e has also been awarded an expansion of its SBIR Phase II grant, to support additional seminal research into the development of new flowable, internal-use hemostatic formulations. This award by the National Science Foundation, is based on the Company's previous success as a Phase I and II recipient.
About gel-e
gel-e is a clinical-stage medical device company developing versatile hemostatic products for surgical, medical, and consumer applications. With an initial focus on external wounds, gel-e combines the use of safe, inert ingredients with proprietary chemistry that can be designed for use across a broad spectrum of clinical applications, including vascular closure and during surgery. gel-e is based in College Park, Md.
For additional information, please visit http://www.gel-e.co.
Contacts:
Larry Tiffany, gel-e, Inc.
(301) 529-4943
pr@gel-e.co
View original content with multimedia:http://www.prnewswire.com/news-releases/gel-e-receives-a-grant-to-develop-new-internal-use-hemostats-300599854.html
SOURCE gel-e, Inc.
